BUCHANAN INGERSOLL & ROONEY PC for GENERIC ANIMAL DRUG ALLIANCE
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Animals ANI
Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions
| Lobbyist | Covered position, as disclosed |
|---|---|
| SOPHIA ESTUPINAN | — |
| MICHAEL P STRAZZELLA | — |
Health Issues HCR
Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions
| Lobbyist | Covered position, as disclosed |
|---|---|
| SOPHIA ESTUPINAN | — |
| MICHAEL P STRAZZELLA | — |
Medical/Disease Research/Clinical Labs MED
Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions
| Lobbyist | Covered position, as disclosed |
|---|---|
| SOPHIA ESTUPINAN | — |
| MICHAEL P STRAZZELLA | — |
Pharmacy PHA
Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions
| Lobbyist | Covered position, as disclosed |
|---|---|
| SOPHIA ESTUPINAN | — |
| MICHAEL P STRAZZELLA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.